BD Predicts Doubling Of Infusion Therapy In Wake Of Ohmeda Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson expects to more than double its infusion therapy (IT) business to $500 mil. in 1999, the first full fiscal year following the company's acquisition of Ohmeda's medical device division, IT worldwide division president Bob Adrion told analysts April 28 in New York City. For 1997, BD reported IT product sales of $228 mil.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.